INDV

Insider Trades

Name	Value	Action	Price	Current Price
Ryan BarbaraDirector $2498 shares BuyMar 13, 2026 $31.09 --
Ryan BarbaraDirector $1.0k31 shares BuyMar 9, 2026 $32.56 --
Kingsley Stuart ADirector $30k940 shares BuyMar 6, 2026 $31.87 --
Wheadon David E.Director $63k1.8k shares BuyJan 5, 2026 $35.39 --
Humphreys KeithDirector $27k775 shares BuyJan 5, 2026 $35.39 --
Ninivaggi Daniel ADirector $27k775 shares BuyJan 5, 2026 $35.39 --

News

fool.comIndivior's Chief Scientific Officer Sold Over 18,000 Company Shares. Should Investors Worry?fool.comJun 13

zacks.comINDV and the Shift to Long-Acting Opioid Use Disorder Care in 2026zacks.comJun 12

zacks.comIs Indivior Stock a Buy After Higher 2026 Guidance?zacks.comJun 12

zacks.comINDV Stock: What Sublocade Growth Signals for 2026zacks.comJun 12

zacks.com5 Top-Ranked Efficient Stocks Beating Industry Peers on Key Metricszacks.comJun 2

Trade INDV

About Indivior Pharmaceuticals Inc

Indivior Pharmaceuticals Inc. operates as a holding company, primarily engaged in the research, production, and distribution of buprenorphine-based prescription medications designed to treat opioid dependence. Its product lineup features key pharmaceuticals such as Suboxone Film, Suboxone Tablet, and Subutex Tablet. The company organizes its business into several geographical regions: the United States, the United Kingdom, and the broader international market. Established on September 26, 2014, its corporate headquarters are located in North Chesterfield, Virginia.

CEO: Joseph J. Ciaffoni
IPO Date: Dec 29, 2014

Market Data

Open: $38.86
High: $39.05
Low: $37.85
Volume: 2.8M
Avg Volume: 2.1M
52W High: $41.00
52W Low: $13.45

Valuation

Market Cap: $4.8B
Enterprise Value: $5.1B
Dividend Yield: 0.00%

Financials

Free Cash Flow: $-93M
Revenue: $1.2B
Net Income: $210M
Cash: $195M
Debt: $351M

Events

EarningsJul 30

EPS est. 0.88